Clark Adam, Wolfe Daniel N
Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Assistant Secretary for Preparedness and Response, Washington, DC, USA.
Microorganisms. 2020 Apr 29;8(5):651. doi: 10.3390/microorganisms8050651.
A licensed anthrax vaccine has been available for pre-exposure prophylaxis in the United States since 1970, and it was approved for use as a post-exposure prophylaxis, in combination with antibiotic treatment, in 2015. A variety of other vaccines are available in other nations, approved under various regulatory frameworks. However, investments in anthrax vaccines continue due to the severity of the threat posed by this bacterium, as both a naturally occurring pathogen and the potential for use as a bioweapon. In this review, we will capture the current landscape of anthrax vaccine development, focusing on those lead candidates in clinical development. Although approved products are available, a robust pipeline of candidate vaccines are still in development to try to address some of the key research gaps in the anthrax vaccine field. We will then highlight some of the most pressing needs in terms of anthrax vaccine research.
自1970年以来，美国就有了一种获得许可的炭疽疫苗用于暴露前预防，2015年它被批准与抗生素治疗联合用于暴露后预防。其他国家有多种其他疫苗，在不同的监管框架下获得批准。然而，由于这种细菌作为自然存在的病原体以及作为生物武器使用的可能性所构成威胁的严重性，对炭疽疫苗的投资仍在继续。在本综述中，我们将介绍炭疽疫苗研发的当前情况，重点关注临床研发中的那些领先候选疫苗。尽管已有获批产品，但仍有一系列强大的候选疫苗正在研发中，以试图填补炭疽疫苗领域的一些关键研究空白。然后，我们将强调炭疽疫苗研究方面一些最紧迫的需求。
